The protein was getting stuck, unable to escape.
For generations, researchers studying hereditary angioedema have had to theorize about a disease they could not directly observe at its cellular origin. Now, for the first time, scientists have grown living liver cells from HAE patients themselves—cells that carry the actual mutations and reveal, with quiet precision, how a single misfolded protein can trap the body in cycles of dangerous swelling. The discovery not only illuminates a long-misunderstood mechanism but suggests that treatments already in use are working through pathways no one had fully mapped.
- HAE patients face sudden, severe swelling attacks because a single protein—C1 esterase inhibitor—fails to leave the liver cells that produce it, leaving the body's inflammatory brakes disengaged.
- Scientists discovered that the protein isn't simply underproduced; it misfolds and clumps inside the endoplasmic reticulum, trapped before it can ever reach the bloodstream.
- Two existing drugs, danazol and dihydrotestosterone, were shown to reduce this protein aggregation and meaningfully improve C1-INH activity in patient cells—without altering gene expression at all.
- The field now has its first renewable, patient-derived liver cell models, closing a decades-long gap in experimental tools for a rare disease that has long resisted direct cellular study.
- These cell lines open the door to preclinical drug screening, personalized gene therapy strategies, and mechanistic research that was simply impossible before this breakthrough.
For decades, scientists studying hereditary angioedema lacked a fundamental tool: living cells from actual patients that could show what goes wrong inside the body in real time. That gap has now closed.
HAE is caused by mutations in the SERPING1 gene, which produces C1 esterase inhibitor—a protein that acts as a brake on the body's inflammatory cascades. When C1-INH is absent or defective, a chemical called bradykinin builds up unchecked, triggering the sudden, severe swelling episodes that define the disease. Researchers took cells from two HAE patients, reprogrammed them into induced pluripotent stem cells, and guided them to become hepatocytes—the liver cells responsible for producing C1-INH. The resulting lines, HAE102 and HAE201, each carried the patient's own mutation and behaved like real liver cells within sixteen days.
What the team observed reframed the disease. The total amount of C1-INH inside the cells appeared roughly normal, but the protein secreted outward was dramatically reduced. High-resolution microscopy revealed the reason: C1-INH was clumping inside the endoplasmic reticulum, misfolding and getting trapped before it could escape. The problem was not simply that less protein was being made—the protein that was made was misbehaving.
When the researchers treated these patient-derived cells with danazol and dihydrotestosterone—androgens already used in HAE care—both drugs reduced the clumping and improved C1-INH activity measurably. Neither drug increased gene expression; the benefit was happening entirely at the protein level, helping misfolded C1-INH behave correctly rather than producing more of it.
Published in the Journal of Allergy and Clinical Immunology, the work represents a watershed for a rare disease long starved of good experimental tools. These renewable cell lines now make it possible to test new therapies in the laboratory, explore gene therapy tailored to individual mutations, and study the disease's mechanics with a clarity that was, until now, out of reach.
For decades, researchers studying hereditary angioedema have worked without a crucial tool: living cells from actual HAE patients that could show them, in real time, what goes wrong inside the body. That gap has now closed. Scientists have created the first liver cell lines derived directly from people with HAE, and in doing so, they've uncovered a mechanism that explains why the disease causes its devastating swelling attacks—and shown that existing treatments work in ways researchers didn't fully understand.
HAE is a rare genetic disorder caused by mutations in a single gene called SERPING1. That gene produces a protein called C1 esterase inhibitor, or C1-INH, which acts as a brake on inflammatory cascades in the body. When C1-INH is missing or broken, the brakes fail. Bradykinin, a potent inflammatory chemical, builds up unchecked, triggering the sudden, severe swelling episodes that define the disease. Nearly all HAE cases stem from SERPING1 mutations—some patients have too little C1-INH protein (type 1), others have normal amounts but defective protein (type 2).
The research team took cells from two HAE patients, reprogrammed them into induced pluripotent stem cells (iPSCs), and then coaxed those cells to become hepatocytes—liver cells, the body's main factory for C1-INH production. They named the resulting cell lines HAE102 and HAE201, each carrying the patient's own SERPING1 mutation. By day 16 of growth, the cells looked and behaved like real liver cells. Now the researchers had a window into the disease at the cellular level.
What they saw was striking. When they compared HAE cells to healthy control cells, the total amount of C1-INH protein inside the cells looked roughly the same. But the amount of C1-INH that actually made it out of the cells—secreted into the surrounding medium—was dramatically lower in HAE cells. Gene expression was cut roughly in half. Yet the reduction in functional protein was even worse than the gene expression numbers alone would predict. Using high-resolution microscopy, the team discovered why: C1-INH was clumping together inside the cells, accumulating in the endoplasmic reticulum, the cellular compartment responsible for folding proteins correctly and shipping them out. The protein was getting stuck, unable to escape.
This finding reframed the disease. It wasn't just that HAE cells made less C1-INH. The protein they did make was misbehaving—folding incorrectly, aggregating, getting trapped. The researchers then tested whether existing HAE drugs could reverse this. They treated the patient-derived cells with danazol and dihydrotestosterone, both androgens already approved or used for HAE. Both compounds reduced the clumping. Danazol raised C1-INH activity in HAE201 cells from 17.55 percent to 26.73 percent. Dihydrotestosterone pushed it higher still, from 27.07 percent to 38.91 percent. Crucially, neither drug increased SERPING1 gene expression. The improvement happened at the protein level—the drugs were helping misfolded C1-INH behave better, not making more of it.
The implications ripple outward. These patient-derived cell lines are renewable and controllable, meaning researchers can now test new drugs in a dish before moving to clinical trials. They can explore gene therapy approaches tailored to individual patients' mutations. They can study the mechanics of the disease in ways that were impossible before. The work, published in the Journal of Allergy and Clinical Immunology, represents a fundamental shift in HAE research—from studying the disease in isolation to studying it in cells that carry the actual mutations of actual patients. For a rare disease that has long lacked good experimental tools, that is a watershed moment.
Notable Quotes
These models not only exhibit key molecular features of HAE but also provide a versatile platform for mechanistic studies and preclinical drug testing.— The research team
The iPSC system enables mechanistic studies, preclinical drug testing, and exploration of gene therapy strategies in a patient-specific context.— The researchers
The Hearth Conversation Another angle on the story
Why did researchers need to create these cell models now? Hadn't they been studying HAE for years?
They had, but always at a distance. They could study the genetics, the protein structure, what happens in blood. But they couldn't watch the disease unfold inside a living cell from an HAE patient. That's a different kind of knowledge.
And what did they discover that they couldn't have known before?
That the C1-INH protein isn't just scarce in HAE cells—it's broken. It misfolds, clumps up, gets stuck inside the cell. It's like a factory worker who shows up but can't get to the assembly line.
Does that change how doctors treat the disease?
Not immediately. But it explains why the drugs that already work actually work. Danazol and dihydrotestosterone aren't making more C1-INH. They're helping the broken protein behave better. That's useful information for designing new treatments.
Could this lead to a cure?
These models open the door to testing gene therapy approaches in patient cells before trying them in people. That's how you find out if a cure might work. But we're not there yet.
What makes these cell lines different from other disease models?
They're patient-derived. They carry the actual mutations from actual people. That means they're not a simplification of the disease—they're the disease, in a dish.